Francesca Magni

Dr. Francesca Magni


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2024 in International Journal of Gynecology & Obstetrics
Verified
Journal Article
Closed access
IPIrene Porcari
Irene Porcari
PZPier Carlo Zorzato
Pier Carlo Zorzato
MBMariachiara Bosco
Mariachiara Bosco
Simone GarzonSimone Garzon
Simone Garzon
FMFrancesca Magni
Francesca Magni
SUStefano Uccella
Stefano Uccella

5 June 2023 in Healthcare
Verified
Journal Article
Open access
PDF file
Filippo Alberto FerrariFilippo Alberto Ferrari
Filippo Alberto Ferrari
FMFrancesca Magni
Francesca Magni
MBMariachiara Bosco
Mariachiara Bosco
GBGiulia Biancotto
Giulia Biancotto
PZPier Carlo Zorzato
Pier Carlo Zorzato
Simone GarzonSimone Garzon
Simone Garzon
There is evidence that diet and nutrition are modifiable risk factors for several cancers. In recent years, attention paid to micronutrients in gynecology has increased, especially regarding Human papillomavirus (HPV) infection. We performed a review of the literature up until December 2022, aiming to clarify the effects of micronutrients, minerals, and vitamins on the history of HPV infection and the development of cervical cancer. We included studies having as their primary objective the evaluation of dietary supplements, in particular calcium; zinc; iron; selenium; carotenoids; and vitamins A, B12, C, D, E, and K. Different oligo-elements and micronutrients demonstrated a potential protective role against cervical cancer by intervening in different stages of the natural history of HPV infection, development of cervical dysplasia, and invasive disease. Healthcare providers should be aware of and incorporate the literature evidence in counseling, although the low quality of evidence provided by available studies recommends further well-designed investigations to give clear indications for clinical practice.

1 September 2020 in Journal of Cardiology
Verified
Journal Article
Closed access
EWEvangeline G. Warmerdam
Evangeline G. Warmerdam
FMFrancesca Magni
Francesca Magni
TLTim Leiner
Tim Leiner
PDP. A. Doevendans
P. A. Doevendans
GSGertjan T. Sieswerda
Gertjan T. Sieswerda
TTTim Takken
Tim Takken

10 April 2025 in Medicina
Verified
Journal Article
Open access
PDF file
PZPier Carlo Zorzato
Pier Carlo Zorzato
Simone GarzonSimone Garzon
Simone Garzon
MBMariachiara Bosco
Mariachiara Bosco
Filippo Alberto FerrariFilippo Alberto Ferrari
Filippo Alberto Ferrari
FMFrancesca Magni
Francesca Magni
SUStefano Uccella
Stefano Uccella
Background and Objectives: To summarize the evidence on in vivo uterine pelvic lymphatic drainage. Materials and Methods: A literature search was performed in multiple electronic databases from inception to December 2024. We included all the studies that compared two different uterine injection sites in the mapping of pelvic sentinel lymph nodes by injecting two different tracers into two distinct injection sites. The primary outcomes included the concordance and discordance rates in the mapped pelvic sentinel lymph nodes between the pairs of injection sites. The secondary outcomes were the detection rates per injection site and tracer. Four reviewers independently reviewed the records for inclusion, assessed the risk of bias, and extracted the data. Pooled concordance, discordance, and detection rates with 95% confidence intervals (CIs) were estimated using the random effects model. Heterogeneity was quantified using the I2 tests. Results: Out of 2512 records, we included 4 studies (172 patients and 344 hemipelves). Three studies injected the cervix with the technetium-99m and the uterine corpus with methylene blue; one study injected the cervix with indocyanine green and the utero-ovarian ligament with methylene blue. Both tracers/injection sites successfully identified a sentinel lymph node in 132 hemipelves (132/344; 38.4%), identifying the same sentinel lymph node in 116 cases (116/132; 87.9%). The pooled concordance rate per hemipelvis was 91.8% (95% CI 0.665–1.000; I2 = 92%; chi2 p-value < 0.01). Two different sentinel lymph nodes were identified in the remaining 16 hemipelves, with a pooled hemipelvis discordance rate of 8.2% (95% CI 0.000–0.335; I2 = 92%; chi2 p-value < 0.01). The cervix and technetium-99m were the injection site and tracer with the highest pooled detection rate. Conclusions: Different uterine injection sites appear to share a common pelvic lymphatic pathway and sentinel lymph node in most cases, consistent with the current practice in endometrial cancer. Future research will confirm whether cervical injections might be proposed for pelvic sentinel lymph node mapping in all gynecological cancers.

14 August 2023 in Journal of Minimally Invasive Gynecology
Verified
Journal Article
Closed access
SUStefano Uccella
Stefano Uccella
FMFrancesca Magni
Francesca Magni
PZPier Carlo Zorzato
Pier Carlo Zorzato
ARAlberta Ricci
Alberta Ricci
AFAlessandro Favilli
Alessandro Favilli
SGSimone Garzon
Simone Garzon

1 September 2025 in Journal of Obstetrics and Gynaecology Research
Verified
Journal Article
Closed access
FMFrancesca Magni
Francesca Magni
Filippo Alberto FerrariFilippo Alberto Ferrari
Filippo Alberto Ferrari
MMMauro Minasola
Mauro Minasola
PZPier Carlo Zorzato
Pier Carlo Zorzato
SGSimone Garzon
Simone Garzon
SUStefano Uccella
Stefano Uccella